4 results
Approved WMOCompleted
To investigate the safety, tolerability and behavior in the body (absorption and excretion) of oral intake of TMC589337 and TMC589354 after ascending single intakes. In addition, the safety, tolerability and behavior in the body after multipe dose…
Approved WMORecruiting
The aim of this study is to investigate non-inferiority of rituximab SC 336 mg to rituximab IV 200 mg.
Approved WMOCompleted
The proportion of patients in GC-free remission after 20 weeks.
Approved WMOCompleted
The sponsor is developing a biological product (DRL_AB) similar to the approved medicine Orencia®. As part of medical-scientific studies to confirm the similarity of the biological products, the Sponsor wants to compare DRL_AB with EU-approved…